||Chinese traditional Chinese medicine has been underestimated by Western modern science, but with the different compounds extracted from various Chinese medicines used to treat diseases which have good effects, therefore, in recent years, Chinese medicine has attracted more and more attention in the medical field. According to ancient Chinese medical literature, Chinese drug are classified into three attribution: cold, medium and heat medicine; Chinese medicine is also classified as Meridian which means that the drug belongs to the meridians it affects. In this study, we attempted to explain the differences between the attribution and meridian of traditional Chinese medicine by analyzing the L1000 expression profile data of cancer cells treated with Chinese drug. After data analysis, we found that functional analysis of differences between various attributes, tastes, and meridian showed different functions between different groups. In addition, we have learned that the pathways leading to the action of cells in some specific properties may affect the development of cancer. Based on this result, we selected four TCMs which mix the attributes and meridians of our interest and we proved three of these drug’s ability of inhibiting MCF7 breast cancer cells through cell biology experiments. Finally, we believe that the results of Chinese medicine classification method studies that explain by the L1000 profile data may be useful for the development of Chinese medicine.|
||1.Li DJ. [Integration of traditional Chinese and Western medicine]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001;21(2):140-1.|
2.Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell. 2011;146(6):855-8.
3.Li WW, Guo H, Li HH, Wang LL, Fu H, Wang XM. Integration of traditional Chinese medicines and Western medicines for treating diabetes mellitus with coronary heart disease: a systematic review. J Altern Complement Med. 2013;19(6):492-500.
4.Ximin. Z, Jipeng. Z, Zheng. W. Analysis on Chinese Herbs Properties of Anti Lung and Colorectal Cancer CHINESE MEDICINE MODERN DISTANCE EDUCATION OF CHINA. 2009:76-7.
5.Zhu YJ, Zhang HB, Liu LR, Liu YH, Zhang FL, Bai JP, et al. Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept. Evid Based Complement Alternat Med. 2017;2017:7063859.
6.Wong WC, Lee A, Wong SY, Wu SC, Robinson N. Strengths, weaknesses, and development of Traditional Chinese Medicine in the health system of Hong Kong: through the eyes of future Western doctors. J Altern Complement Med. 2006;12(2):185-9; discussion 91-2.
7.Wu J, Xie J, Zhang QL, Lin ZX, Xie H, Sun B. [Research progress on meridian-guiding theory of traditional Chinese medicine]. Zhongguo Zhong Yao Za Zhi. 2016;41(13):2428-34.
8.Shifeng. Overview of Research on Traditional Chinese Medicinine Channel Tropism. Journal Of Liaoning University of TCM. 2014(03- 0127- 04):03-4.
9.Gu H, Zhang YL, Wang Y, Qiao YJ. [Study on characteristics of pharmacological effects of traditional Chinese medicines distributing along lung meridian based on medicinal property combination]. Zhongguo Zhong Yao Za Zhi. 2014;39(13):2400-3.
10.Ma H, Horiuchi KY. Chemical microarray: a new tool for drug screening and discovery. Drug Discov Today. 2006;11(13-14):661-8.
11. Feferman T, Aricha R, Menon R, Souroujon MC, Berrih-Aknin S, Fuchs S. DNA microarray in search of new drug targets for myasthenia gravis. Ann N Y Acad Sci. 2007;1107:111-7.
12.Duan Q, Reid SP, Clark NR, Wang Z, Fernandez NF, Rouillard AD, et al. L1000CDS(2): LINCS L1000 characteristic direction signatures search engine. NPJ Syst Biol Appl. 2016;2.
13.Wang Z, Clark NR, Ma′ayan A. Drug-induced adverse events prediction with the LINCS L1000 data. Bioinformatics. 2016;32(15):2338-45.
14.Duan Q, Flynn C, Niepel M, Hafner M, Muhlich JL, Fernandez NF, et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 2014;42(Web Server issue):W449-60.
15.Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171(6):1437-52 e17.
16.Liu C, Su J, Yang F, Wei K, Ma J, Zhou X. Compound signature detection on LINCS L1000 big data.(2) Mol Biosyst. 2015;11(3):714-22.
17.Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171(6):1437-52 e17.
18.Liu J, Wang S, Zhang Y, Fan HT, Lin HS. Traditional Chinese medicine and cancer: History, present situation, and development. Thorac Cancer. 2015;6(5):561-9.
19. Liu JX, Shi ZM, Xu ZY. Studies on late primary adenocarcinoma of lung treated by methods of nourishing yin to replenish fluid and warming Yang to benefit Qi. J Tradit Chin Med. 1995;36:155–158.
20. Xu ZY, Jin CJ, Zhou CC, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol. 2011;137:1117–1122.
21. Zhang DZ, Xu JD. Clinical and experimental researches on improving radiation sensibility for lung cancer patients. Chin J Surg Integr Tradit West Med. 1998;4:71–75. (In Chinese.)
22. Zhou DH, Lin LZ, Zhou YQ. Effect of Chinese herbal medicine in prolonging median survival time in patients with non-small-cell lung cancer. J Guangzhou Univ Tradit Chin Med. 2005;7:255–258.